ABOUND.2L+: A randomized phase 2 study of nanoparticle albumin‐bound paclitaxel with or without CC‐486 as second‐line treatment for advanced nonsquamous non‐small cell lung cancer (NSCLC)

ABOUND.2L+: A randomized phase 2 study of nanoparticle albumin‐bound paclitaxel with or without CC‐486 as second‐line treatment for advanced nonsquamous non‐small cell lung cancer (NSCLC)

<p><strong>Background</strong> This randomized phase 2 trial compared the efficacy and safety of second‐line nanoparticle albumin‐bound paclitaxel (nab‐paclitaxel) with or without the addition of CC‐486 (an oral formulation of 5‐azacytidine) in patients with advanced‐stage, nonsqua...

ver descrição completa

Detalhes bibliográficos
Principais autores:	Morgensztern, D, Cobo, M, Ponce Aix, S, Postmus, PE, Lewanski, CR, Bennouna, J, Fischer, JR, Juan-Vidal, O, Stewart, DJ, Fasola, G, Ardizzoni, A, Bhore, R, Wolfsteiner, M, Talbot, DC, Jin Ong, T, Govindan, R, On Behalf Of The Abound L Investigators
Formato:	Journal article
Idioma:	English
Publicado em:	Wiley 2018

Registros relacionados

ABOUND.2L+: nab-paclitaxel (nab-P) +/- CC-486 or durvalumab in previously treated patients with advanced non-small cell lung cancer (NSCLC)
por: Morgensztern, D, et al.
Publicado em: (2017)

Efficacy and safety of second- or third-line nab-paclitaxel + durvalumab in patients with advanced NSCLC (ABOUND.2L+)
por: Morgensztern, D, et al.
Publicado em: (2018)

Quality of life in patients with advanced NSCLC treated in second- or third-line with nab-paclitaxel + durvalumab: abound.2l+
por: Talbot, D, et al.
Publicado em: (2018)

Nab-paclitaxel + durvalumab as second- or third-line treatment of advanced NSCLC: results from ABOUND.2l+
por: Govindan, R, et al.
Publicado em: (2017)

nab-Paclitaxel Plus Durvalumab in Patients With Previously Treated Advanced Stage Non-small Cell Lung Cancer (ABOUND.2L+)
por: Daniel Morgensztern, et al.
Publicado em: (2021-02-01)

Quality of life with second or third line nab-paclitaxel-based regimens in advanced non-small-cell lung cancer
por: Ponce Aix, S, et al.
Publicado em: (2020)

nab-Paclitaxel-Based Therapy in Underserved Patient Populations: The ABOUND.70+ Study in Elderly Patients With Advanced NSCLC
por: Corey J. Langer, et al.
Publicado em: (2018-07-01)

nab-Paclitaxel/Carboplatin in Vulnerable Populations With Advanced Non-Small Cell Lung Cancer: Pooled Analysis
por: Corey J. Langer, et al.
Publicado em: (2021-01-01)

Pharmacokinetics and Pharmacodynamics with Extended Dosing of CC-486 in Patients with Hematologic Malignancies.
por: Eric Laille, et al.
Publicado em: (2015-01-01)

nab-Paclitaxel–Based Therapy in Underserved Patient Populations: The ABOUND.PS2 Study in Patients With NSCLC and a Performance Status of 2
por: Ajeet Gajra, et al.
Publicado em: (2018-07-01)

The uses of anxiety: Grace Abounding to the Chief of Sinners (1666)
por: Seymour, L
Publicado em: (2023)

Short Toxin-like Proteins Abound in Cnidaria Genomes
por: Michal Linial, et al.
Publicado em: (2012-11-01)

Misperceptions of "light" cigarettes abound: National survey data
por: Thomson George, et al.
Publicado em: (2009-05-01)

Aboundance, Diversity and Distribution of Ichthyoplanktons in Creeks and Coastal Waters of Khouzestan Province
por: S. Dehghan; A. Savari; P. Kochenin; J. Ghafle marammazi
Publicado em: (1999-01-01)

The Jurisdictional Basis, Elements and Remedies in the Action for Breach of Confidence - Uncertainty Abounds
por: Leo Tsaknis

Features of fibrosis regression abound in "non-cirrhotic" patients with resected hepatocellular carcinoma.
por: Christine E Orr, et al.
Publicado em: (2022-01-01)

Improbabilities abound”: Daphne du Maurier’s Rule Britannia and the speculative political future
por: Aoife Byrne
Publicado em: (2015-07-01)

Features of fibrosis regression abound in “non-cirrhotic” patients with resected hepatocellular carcinoma
por: Christine E. Orr, et al.
Publicado em: (2022-01-01)

Ultrafast Gene Fusion Assessment for Nonsquamous NSCLC
por: Véronique Hofman, MD, PhD, et al.
Publicado em: (2023-02-01)

Phase III, randomized, placebo-controlled trial of CC-486 (Oral Azacitidine) in patients with lower-risk myelodysplastic syndromes
por: Garcia-Manero, G, et al.
Publicado em: (2021)

An open-label, phase II multicohort study of an oral hypomethylating agent CC-486 and durvalumab in advanced solid tumors
por: Neda Stjepanovic, et al.
Publicado em: (2020-10-01)

Exodus, Psalms and Hebrews: A God abounding in steadfast love (Ex 34:6)
por: Alphonso Groenewald
Publicado em: (2008-03-01)

Efficacy of paclitaxel‐carboplatin with bevacizumab as a late‐line therapy for patients with advanced nonsquamous non‐small cell lung cancer: A platinum rechallenge
por: Jun Sugisaka, et al.
Publicado em: (2023-11-01)

Ticks and Tick-Borne Pathogens Abound in the Cattle Population of the Rabat-Sale Kenitra Region, Morocco
por: Latifa Elhachimi, et al.
Publicado em: (2021-12-01)

Soils rich in biological ice-nucleating particles abound in ice-nucleating macromolecules likely produced by fungi
por: F. Conen, et al.
Publicado em: (2018-07-01)

Length Frequency, Sex Ratio and Relative Aboundance (CPUE) of Astacus leptoductylus in Arass Reservior (1997-98)
por: M. Karimpor; N. Hosseinpor
Publicado em: (1999-01-01)

Phase II study of carboplatin/nab-paclitaxel/atezolizumab combination therapy for advanced nonsquamous non–small cell lung cancer patients with impaired renal function: RESTART trial
por: Yoshimasa Shiraishi, et al.
Publicado em: (2022-09-01)

Computer processor unit 486
por: Universiti Teknologi Malaysia. Perpustakaan
Publicado em: (1989)

nab-Paclitaxel/carboplatin in elderly patients with advanced squamous non-small cell lung cancer: a retrospective analysis of a Phase III trial
por: Gridelli C, et al.
Publicado em: (2018-05-01)

Androgen Receptor Expression in Primary Nonsquamous Cell Rare-Variant Carcinomas of the Head and Neck
por: Siavash Rahimi MD, FRCPath, et al.
Publicado em: (2017-06-01)

Multicenter study of carbon‐ion radiation therapy for nonsquamous cell carcinomas of the oral cavity
por: Hiroaki Ikawa, et al.
Publicado em: (2019-09-01)

A Real-World Study on the Effectiveness and Safety of Pembrolizumab Plus Chemotherapy for Nonsquamous NSCLC
por: Daichi Fujimoto, MD, et al.
Publicado em: (2022-02-01)

Gemcitabine: Efficacy in the Treatment of Advanced Stage Nonsquamous Non-Small Cell Lung Cancer
por: Hidetoshi Hayashi, et al.
Publicado em: (2011-01-01)

P540: RESULTS FROM A PHASE 1 CLINICAL STUDY OF THE ALL-ORAL REGIMEN OF CC-486 AND VENETOCLAX FOR RELAPSED AND REFRACTORY ACUTE MYELOID LEUKEMIA (AML)
por: Maria Amaya, et al.
Publicado em: (2023-08-01)

KIE 486 - KIMIA MAKANAN JUN 1994.
por: PPSK, Pusat Pengajian Sains Kimia
Publicado em: (1994)

Brief Report: Impact of Maintenance Pemetrexed Cessation on Clinical Outcomes of Patients With Metastatic Nonsquamous NSCLC
por: Shreya Bhatia, BS, et al.
Publicado em: (2024-11-01)

Biomarker Testing for Patients With Advanced/Metastatic Nonsquamous NSCLC in the United States of America, 2015 to 2021
por: Lisa M. Hess, PhD, et al.
Publicado em: (2022-06-01)

Bevacizumab in the treatment of nonsquamous non-small cell lung cancer: clinical trial evidence and experience
por: Laurent Greillier, et al.
Publicado em: (2016-10-01)

An Epidemiologic study of Oral and Pharyngeal Nonsquamous Cell Malignant Tumors inKerman province, Iran
por: MR. Zarei, et al.
Publicado em: (2007-03-01)

Glenn's Suzuki one-cylinder repair and tune-up guide : models 50 cc, 55 cc, 80 cc, 90 cc, 120 cc, 125 cc, 185 cc, 250 cc, 400 cc/
por: 402466 Crawford, Charles W., et al.
Publicado em: (1972)